BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Trading Down 9.4% – Here’s Why

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) shares fell 9.4% on Wednesday . The company traded as low as $8.17 and last traded at $8.03. Approximately 123,171 shares were traded during trading, a decline of 65% from the average daily volume of 348,500 shares. The stock had previously closed at $8.86.

Analyst Ratings Changes

BBOT has been the topic of a number of analyst reports. UBS Group cut BridgeBio Oncology Therapeutics to an “overweight” rating in a report on Wednesday, July 8th. Wedbush reaffirmed an “outperform” rating and set a $25.00 price target on shares of BridgeBio Oncology Therapeutics in a research note on Wednesday. Stifel Nicolaus lowered their price target on shares of BridgeBio Oncology Therapeutics from $23.00 to $15.00 and set a “buy” rating for the company in a report on Wednesday. Canaccord Genuity Group set a $20.00 price objective on shares of BridgeBio Oncology Therapeutics in a research report on Wednesday. Finally, Raymond James Financial restated an “outperform” rating and set a $22.00 target price on shares of BridgeBio Oncology Therapeutics in a research report on Wednesday. Eight investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, BridgeBio Oncology Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $22.57.

BridgeBio Oncology Therapeutics Trading Down 15.6%

The stock’s 50-day moving average is $8.79 and its 200-day moving average is $8.75. The stock has a market cap of $599.62 million, a price-to-earnings ratio of -2.72 and a beta of 0.38.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($705.20) EPS for the quarter. On average, equities analysts predict that BridgeBio Oncology Therapeutics, Inc will post -2.79 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BridgeBio Oncology Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC raised its position in shares of BridgeBio Oncology Therapeutics by 3.8% during the 4th quarter. Geode Capital Management LLC now owns 561,987 shares of the company’s stock valued at $7,039,000 after acquiring an additional 20,385 shares in the last quarter. Goldman Sachs Group Inc. acquired a new position in BridgeBio Oncology Therapeutics in the fourth quarter worth $1,185,000. BIT Capital GmbH bought a new stake in BridgeBio Oncology Therapeutics during the fourth quarter valued at $313,000. CIBC Private Wealth Group LLC bought a new position in shares of BridgeBio Oncology Therapeutics in the 4th quarter worth about $63,000. Finally, Renaissance Technologies LLC bought a new stake in shares of BridgeBio Oncology Therapeutics during the 4th quarter valued at about $930,000. Institutional investors own 54.89% of the company’s stock.

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.